Methods of delivery of cetyl myristoleate

Abstract

The invention provides novel and advantageous delivery devices for compositions of cetyl myristoleate. The delivery devices include transdermal delivery devices, suppositories, enteric coatings, and microencapsulation. Further provided are methods of treating diseases using the disclosed delivery devices. Diseases that can be treated with the devices include, but are not limited to, diseases associated with the inflammation of tissues, diseases associated with inflammatory conditions affecting joints, and autoimmune diseases.

1 . A transdermal delivery device for the delivery of cetyl myristoleate wherein the transdermal delivery device contains between 1 mg and 3000 mg of cetyl myristoleate.  
     
     
         2 . The transdermal delivery device of  claim 1  comprising: 
 a backing layer; and  
 a matrix layer underlying the backing layer, the matrix layer comprising a mixture of cetyl myristoleate and a pressure sensitive adhesive.  
 
     
     
         3 . The transdermal delivery device of  claim 1  wherein said matrix layer further comprises one or more of the components selected from the group consisting of glucosamine sulfate, chondroitin sulfate, sea cucumber extract, hydrolyzed shark cartilage, collagen II, and methylsulfonylmethane.  
     
     
         4 . The transdermal delivery device of  claim 1  wherein the device is worn for between 5 and 10 days.  
     
     
         5 . The transdermal delivery device wherein between 0.01 mg/kg/day and 10 mg/kg/day of cetyl myristoleate is delivered.  
     
     
         6 . A method of treating a disease associated with the inflammation of tissues comprising affixing to the skin of an animal or human the transdermal delivery device of  claim 1  wherein said disease is selected from the group consisting of tendinitis, tenosynovitis, bursitis, chronic patellar tendinitis, Achilles tendinitis, fibrositis, inflammation of the spine, colitis, bronchitis, polymyalagia rheumatica, Crohn's disease, primary biliary cirrhosis, pericarditis, ulcerative colitis, and Sjogren's syndrome.  
     
     
         7 . A method of treating a disease associated with an inflammatory condition that affects joints comprising affixing to the skin of an animal or human the transdermal delivery device of  claim 1  wherein said disease is selected from the group consisting of arthritis, chronic arthritis, Behcet's disease, ankylosing spondylitis, mixed connective tissue disease, Reiter's syndrome, and synovitis.  
     
     
         8 . A method of treating an autoimmune disease comprising affixing to the skin of an animal or human the transdermal delivery device of  claim 1  wherein said disease is selected from the group consisting of autoimmune Addison's disease, autoimmune hepatitis, Behcet's disease, lupus, antiphospholipid syndrome, multiple sclerosis, and essential mixed cryoglobulinemia.  
     
     
         9 . An oral medicament comprising cetyl myristoleate and an enteric coating, said coating being resistant to dissolution in the stomach but predisposed to dissolution in the intestine so as to prevent release of said cetyl myristoleate until said medicament is in the intestine.  
     
     
         10 . The oral medicament of  claim 9 , wherein said enteric coating is resistant to dissolution in an environment having a pH less than about 5.5.  
     
     
         11 . The oral medicament of  claim 9  wherein said oral medicament comprises between 0.1 g and 1 g of cetyl myristoleate.  
     
     
         12 . The oral medicament of  claim 9 , wherein said oral medicament further comprises one or more of the components selected from the group consisting of glucosamine sulfate, chondroitin sulfate, sea cucumber extract, hydrolyzed shark cartilage, collagen II, and methylsulfonylmethane.  
     
     
         13 . A method of treating a disease associated with the inflammation of tissues comprising administering to a human or animal the oral medicament of  claim 9 , wherein said disease is selected from the group consisting of tendinitis, tenosynovitis, bursitis, chronic patellar tendinitis, Achilles tendinitis, fibrositis, inflammation of the spine, colitis, bronchitis, polymyalagia rheumatica, Crohn's disease, primary biliary cirrhosis, pericarditis, ulcerative colitis, and Sjogren's syndrome.  
     
     
         14 . A method of treating a disease associated with an inflammatory condition that affects joints administering to a human or animal the oral medicament of  claim 9 , wherein said disease is selected from the group consisting of arthritis, chronic arthritis, Behcet's disease, ankylosing spondylitis, mixed connective tissue disease, Reiter's syndrome, and synovitis.  
     
     
         15 . A method of treating an autoimmune disease comprising administering to a human or animal the oral medicament of  claim 9 , wherein said disease is selected from the group consisting of autoimmune Addison's disease, autoimmune hepatitis, Behcet's disease, lupus, antiphospholipid syndrome, multiple sclerosis, and essential mixed cryoglobulinemia.  
     
     
         16 . An oral medicament comprising microencapsulated cetyl myristoleate, said microencapsulation being resistant to dissolution in the stomach but predisposed to dissolution in the intestine so as to prevent release of said cetyl myristoleate until said medicament is in the intestine.  
     
     
         17 . The oral medicament of  claim 16 , wherein said oral medicament comprises between 0.1 g and 1 g of cetyl myristoleate.  
     
     
         18 . The oral medicament of  claim 16 , wherein said oral medicament further comprises one or more of the components selected from the group consisting of glucosamine sulfate, chondroitin sulfate, sea cucumber extract, hydrolyzed shark cartilage, collagen II, and methylsulfonylmethane.  
     
     
         19 . A method of treating a disease associated with the inflammation of tissues comprising administering to a human or animal the oral medicament of  claim 16 , wherein said disease is selected from the group consisting of tendinitis, tenosynovitis, bursitis, chronic patellar tendinitis, Achilles tendinitis, fibrositis, inflammation of the spine, colitis, bronchitis, polymyalagia rheumatica, Crohn's disease, primary biliary cirrhosis, pericarditis, ulcerative colitis, and Sjogren's syndrome.  
     
     
         20 . A method of treating a disease associated with an inflammatory condition that affects joints administering to a human or animal the oral medicament of  claim 16 , wherein said disease is selected from the group consisting of arthritis, chronic arthritis, Behcet's disease, ankylosing spondylitis, mixed connective tissue disease, Reiter's syndrome, and synovitis.  
     
     
         21 . A method of treating an autoimmune disease comprising administering to a human or animal the oral medicament of  claim 16 , wherein said disease is selected from the group consisting of autoimmune Addison's disease, autoimmune hepatitis, Behcet's disease, lupus, antiphospholipid syndrome, multiple sclerosis, and essential mixed cryoglobulinemia  
     
     
         22 . A suppository for transrectal or transurethral delivery comprising cetyl myristoleate in combination with a physiologically acceptable solid carrier that is meltable at human or animal body temperature.  
     
     
         23 . The suppository of  claim 22  wherein the suppository comprises between 1 mg and 3000 mg of cetyl myristoleate.  
     
     
         24 . The suppository of  claim 22  further comprising one or more of the components selected from the group consisting of glucosamine sulfate, chondroitin sulfate, sea cucumber extract, hydrolyzed shark cartilage, collagen II, and methylsulfonylmethane  
     
     
         25 . A method of treating a disease associated with the inflammation of tissues comprising administering to a human or animal the suppository of  claim 22 , wherein said disease is selected from the group consisting of tendinitis, tenosynovitis, bursitis, chronic patellar tendinitis, Achilles tendinitis, fibrositis, inflammation of the spine, colitis, bronchitis, polymyalagia rheumatica, Crohn's disease, primary biliary cirrhosis, pericarditis, ulcerative colitis, and Sjogren's syndrome.  
     
     
         26 . A method of treating a disease associated with an inflammatory condition that affects joints administering to a human or animal the suppository of  claim 22 , wherein said disease is selected from the group consisting of arthritis, chronic arthritis, Behcet's disease, ankylosing spondylitis, mixed connective tissue disease, Reiter's syndrome, and synovitis.  
     
     
         27 . A method of treating an autoimmune disease comprising administering to a human or animal the suppository of  claim 22 , wherein said disease is selected from the group consisting of autoimmune Addison's disease, autoimmune hepatitis, Behcet's disease, lupus, antiphospholipid syndrome, multiple sclerosis, and essential mixed cryoglobulinemia.